

22.05.2025

Annual Meeting

NAMUR CANCER RESEARCH POLE

University of Namur, Pedro Arrupe, PA02 auditorium

08:15 *Welcome coffee*09:00 *Introduction*

CANCER METABOLISM

09:05 **Metabolic signaling driving cancer metastasis**

Prof. Sarah-Maria FENDT, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven

09:50 **Identification of targetable metabolic adaptations in drug tolerant BRAF^{V600E} mutant non-small cell lung cancer**

Marine HEMMER, Laboratory of Tumor and Development Biology, GIGA-Cancer, ULiège

10:05 **The fatty connection of telomeres**

Amélie DERUMIER, Genetic & Epigenetic Alterations of Genomes, de Duve Institute, UCLouvain

10:20 *Sponsor talks (5')*

Discover a whole new dimension with the new BD FACSDiscover™ A8 Cell Analyzer with Real-Time Imaging

Stefano BONELLI, Product Manager Research BD Biosciences

Isogen Life Science, Making your research happen

Noria KABAGWIRA, Business Development Manager at Isogen Life Science

Empowering Discovery – Advancing Cell Therapy

Ruben BEUK, Marketing Manager at Miltenyi Biotec

Title to be confirmed

Jean-Luc HENRIOUL, Chief Operating Officer at Seqalis

10:40 *Coffee break*

- 11:10 **Targeting oncogene-induced metabolic vulnerabilities in lung cancer**
Dr. Arnaud BLOMME, Laboratory of Metabolic Regulation, GIGA Institute, ULiège
- 11:55 **Vitamin B2 depletion induces stress and 2HG-dependent metabolic remodelling in cancer cells**
Ying Thong LOW, Francis Crick Institute, UK
- 12:10 **The role of DNA oxidative damage in cancer mutagenesis: insights from vertical ionization potential analysis**
Benoît DE WITTE, Computational Biology and Bioinformatics, ULB
- 12:25 **A cellular and molecular perspective on adult acinar cell proliferation in pancreatic tissue regeneration and disease**
Dr. Jonathan BALDAN, Translational Oncology Research Center, VUB
- 12:40 *Lunch & poster session*

NEW ADVANCES IN CANCER THERAPY

- 14:00 **Understanding evolutionary trajectories of Barrett's to intercept oesophageal cancer**
Prof. Rebecca FITZGERALD, Early Cancer Institute, University of Cambridge, UK
- 14:45 **Synthetic lethality between SHIP2 and p53 provides therapeutic opportunity in esophageal squamous cell carcinoma**
Cyril BODART, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM), ULB
- 15:00 **Targeted peptide strategy against anaplastic thyroid carcinoma: EGFR-mediated delivery and PIP3-driven inhibition of the PAM pathway**
Zehra-Cagla KAHVECIOGLU, NMR and Molecular Imaging Laboratory, General, Organic and Biomedical Chemistry Unit, UMONS
- 15:15 **Preventing radiotherapy osteoradionecrosis through extracellular vesicle technology**
Marie-Eugénie DE MEESTER, Clinical Cellular Therapy Research Laboratory, Radiobiology Research Unit, Jules Bordet Institut, ULB
- 15:30 *Group picture*
- 15:35 *Coffee break*
- 16:10 **Venom peptides as a source of novel anti-cancer molecules**
Dr. Sébastien DUTERTRE, Institut des Biomolécules Max Mousseron (IBMM), University of Montpellier, France
- 16:55 **Heterogeneous and dynamic response of squamous esophageal cancer to CDK4/6 inhibition**
Prof. Xavier BISTEAU, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM), ULB
- 17:10 **Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy**
Prof. Dmitri KRYSKO, Cell Death Investigation and Therapy (CDIT) Laboratory, Ghent University; Cancer Research Institute Ghent
- 17:25 *Closing remarks*
- 17:30 *Cheese & Beer*

POSTERS

- P1 Construction of a murine neuroblastoma single cell reference atlas (NBMAP)**
Rizwan AHMAD, Pediatric Precision Oncology Lab, Ghent University; Cancer Research Institute Ghent
- P2 ADAMTS12 in lipid metabolism and tumor progression**
Esther ARPIGNY, Laboratory of Connective Tissue Biology, GIGA-Cancer, ULiège
- P3 Consequences of the inactivation of the mannose-6-phosphate pathway on the growth and drug sensitivity of cancer cells**
Asena AYNACI, Laboratory of Intracellular Trafficking Biology, URPhyM, NARILIS, UNamur
- P4 Deciphering the role of TRMT10C in breast cancer**
Francisca CANULEF, Laboratory of Cancer Epigenetics, ULB
- P5 immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse model**
Morgane COGELS, Department of Radiotherapy, Institut Jules Bordet; Radiophysics Laboratory, ULB
- P6 tRNA editing by the adenosine deaminase ADAT2 regulates colon homeostasis and controls colon cancer progression**
Rossana DE PINTO, Laboratory of Cancer Signaling / Laboratory of Metabolic Regulation, GIGA-Cancer, ULiège
- P7 Development of a novel theranostic boron-containing nanovector to enhance Boron Neutron Capture Therapy effectiveness in head and neck cancers**
Dr. Géraldine DESCAMPS, NMR and Molecular Imaging Laboratory, General, Organic and Biomedical Chemistry Unit, UMONS
- P8 Elucidating the influence of the KrasG12D mutation on small intestinal mucosal immunity**
Lysa DHULST, de Duve Institute, UCLouvain
- P9 Therapeutic targeting of class 2 & 3 BRAF mutated lung adenocarcinoma**
Laurine DUPRIEZ, Laboratory of Tumor and Development Biology, GIGA-Cancer, ULiège
- P10 Assessing the effects of estrogenic and menopause treatments on the microenvironment in ER-negative cancers**
Camille FLAS, Laboratory of Tumor and Development Biology, GIGA-Cancer, ULiège
- P11 Identification of potential anticancer peptides from animal venoms using mass spectrometry techniques**
Lou FREUVILLE, Laboratory of Mass Spectrometry, MolSys Research Unit, ULiège; Laboratory of Molecular Cancer Biology, URPhyM, NARILIS, UNamur

- P12 SHIP2–PLK1 crosstalk promotes synergistic weakness to dual inhibition in esophageal squamous cell carcinoma**
Nadia GILLET, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM), ULB
- P13 Adaptation of fibroblasts in the metastatic niche of tumor-draining lymph nodes**
Noémie GUBBELS, Laboratory of Tumor and Development Biology, GIGA-Cancer, ULiège
- P14 Model-based approaches in CAR-T cell development and assessment: bridging scientific research and regulatory applications**
Lisa HANQUET, Clinical Pharmacology and Toxicology Research Unit, NARILIS, UNamur
- P15 Liquid biopsy: measuring circulating H3K27Me3-nucleosomes in Lung Cancer patients is a strong prognostic biomarker and a potential aid in treatment selection**
Dr. Marielle HERZOG, Research and Development, Belgian Volition
- P16 Direct comparison of anti-tumoral efficiency of ¹⁷⁷Lu and ²²⁵Ac radiolabeled-cetuximab in a mouse model**
Dr. Lionel LARBANOIX, Center for Microscopy and Molecular Imaging, UMONS
- P17 Synthesis and evaluation of the radiosensitising potential of iron oxide nanoparticles functionalized by a platinum complex**
Valentin LECOMTE, NMR and Molecular Imaging Laboratory, General, Organic and Biomedical Chemistry Unit, UMONS
- P18 Mesoporous silica nanoparticles for combined ¹⁹F MRI imaging and boron neutron capture therapy (BNCT)**
Amandine MAES, NMR and Molecular Imaging Laboratory, General, Organic and Biomedical Chemistry Unit, UMONS
- P19 RNA modifications in triple negative breast cancer**
Lorris MAUCLET, Laboratory of Biochemistry and Cell Biology, NARILIS, UNamur
- P20 Targeting ferroptosis resistance to sensitise cancer cells to radiotherapy/protontherapy**
Keïla OPELE-NAVENGE, Laboratory of Analysis by Nuclear Reactions (LARN), NARILIS, UNamur
- P21 Elp3 loss shapes tumor associated neutrophils in metastatic breast cancer**
Lobna OUESLATI, Laboratory of Cancer Signaling, GIGA-Cancer, ULiège
- P22 Determination of the genes involved in intrinsic resistance to proton beam therapy for the treatment of glioblastoma.**
Hortence PARÉE, Laboratory of Biochemistry and Cell Biology, NARILIS, UNamur
- P23 Fibronectin leucine-rich transmembrane protein 3 is a potential driver of tumor progression in intrahepatic cholangiocarcinoma**
Lara PRATES, de Duve Institute, UCLouvain

- P24 TOF-SIMS as a tool to study the alteration of membrane lipids in breast cancer cells after X-Ray and UHDR proton irradiation**
Charlotte ROSSI, NARILIS / NISM, UNamur
- P25 ADAMTS2 in cancer progression: Friend or Foe?**
Louis STOCK, Laboratory of Connective Tissue Biology, GIGA-Cancer, ULiège
- P26 Translation reprogramming drives therapy resistance in metastatic luminal breast cancer**
Miguel SUSAETA RUIZ, Laboratory of Cancer Signaling, GIGA-Cancer, ULiège
- P27 Understanding the consequences of a GlcNAc-1-phosphotransferase inactivation on cancer cell behavior**
Maxence TOUSSAINT, Laboratory of Intracellular Trafficking Biology, URPhyM, NARILIS, UNamur
- P28 Does the radiation LET affect the immunogenicity of cancer cells?**
Manon VAN DEN ABBEEL, Laboratory of Biochemistry and Cell Biology, NARILIS, UNamur
- P29 Advances in liquid biopsy for glioblastoma diagnosis and cancer therapy monitoring through nucleosome epigenetic modifications tracking**
Dr. Priscilla VAN DEN ACKERVEKEN, Research and Development, Belgian Volition
- P30 Role of tumor-stroma metabolic crosstalk in the resistance to anti-EGFR therapy in head and neck cancers**
Engy VIGNERON, Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), UCLouvain
- P31 Pulsed estrogen therapies and endocrine treatment in breast cancer resistance**
Manon ZIELONKA, Laboratory of Tumor Biology and Development, GIGA-Cancer, ULiège

We thank our sponsors !

Gold sponsors



Silver sponsors

